Exclusive CRISPR Licenses ‘Bottleneck’ Innovation, Legal Experts Argue
Licensing deals cut by UC Berkeley and Massachusetts’ Broad Institute may be limiting the potentially lie-saving applications of this gene-editing technology, according to assertions made by intellectual property experts in Friday’s issue of the journal Science.
Exclusive CRISPR Licenses Slow Development Of Therapies, Legal Experts Argue
The exclusive licenses granted to three for-profit companies on key discoveries about the revolutionary genome-editing technology CRISPR-Cas9 threaten to “bottleneck” its use “to discover and develop useful human therapeutics,” patent experts argued in a paper published on Thursday. What the exclusive licenses have done “is give an entire industry to … companies that will never be able to fully exploit it,” Jorge Contreras of the University of Utah, a co-author of the paper in Science, said in an interview. “And that may hold back the development of therapies.” (Begley, 2/16)
The Mercury News:
How UC Berkeley's CRISPR License Could Limit Innovation
A smart biotech company could have a great idea for how to use gene editing to develop a new lifesaving therapy — but because of the way licensing deals have been cut by UC-Berkeley and Massachusetts’ Broad Institute, it would never get a chance to try it. That’s the assertion of intellectual property experts in Friday’s issue of the journal Science, who criticize the licensing landscape around the taxpayer-funded and powerful new tool called CRISPR-Cas9, warning it could limit its promise. “The way universities license biotechnology — through for-profit surrogate companies — may ultimately hinder innovation,” according to intellectual property attorneys Jacob Sherkow of New York Law School in New York, who co-wrote the new paper with Jorge Contreras of the University of Utah. (Krieger, 2/16)